日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma

EZH2是侵袭性和增殖性肝母细胞瘤的关键预后标志物和治疗靶点。

Khoubai, Fatma Zohra; Calovoulos, Alexia; Guillorit, Hélène; Carrillo-Reixach, Juan; Del Rio-Alvarez, Alvaro; Klein, Pierre; Coma, Marina Simon; Avignon, Christophe; Rousseau, Benoit; Mora Charrot, Lea; Fedou, Sandrine; Dupuy, Jean-William; Royo, Laura; Domingo-Sàbat, Montse; Thézé, Nadine; Siegfried, Géraldine; Khatib, Abdel-Majid; Cairo, Stefano; Indersie, Emilie; Jain, Buddhi Prakash; Trézéguet, Véronique; Gontier, Etienne; Lamoureux, François; Guettier, Catherine; Mussini, Charlotte; Hagedorn, Martin; Armengol, Carolina; Grosset, Christophe F

Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase.

EZH2甲基转移酶对染色体不稳定性进行表观遗传调控。

Bai Yang, Agustinus Albert S, Yomtoubian Shira, Meydan Cem, McNally Dylan R, Yoffe Liron, Hubisz Melissa J, Tranquille Marvel, Pramod Sneha, Hong Christy, Plasilova Magdalena L, Kapoor Aakanksha R, Singh Arshdeep, Withers Henry, Dow Lukas E, Laughney Ashley M, Bhinder Bhavneet, Elemento Olivier, Melnick Ari M, Bakhoum Samuel F, Mittal Vivek

Noncanonical EZH2 activity cooperates with FOXM1 to drive tumorigenesis and advanced progression in HCC

非经典 EZH2 活性与 FOXM1 协同作用,驱动肝细胞癌的肿瘤发生和进展。

Jung, Sungju; Bang, Hyun Jin; Park, Myong-Suk; Lee, Kyung Hwa; Hennighausen, Lothar; Yoo, Kyung Hyun; Bae, Woo Kyun

EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression.

EZH2抑制可使前列腺癌谱系变异进化多样化,但对抑制疾病进展缺乏疗效。

Jacobi Justine J, Wadosky Kristine M, Jaiswal Neha, Zhang Xiaojing, Wang Yanqing, Singh Prashant K, Wang Jie, Cortes Gomez Eduardo, Wang Jianmin, Xu Bo, Long Mark D, Cejas Paloma, Kukreja Shweta, Long Henry W, Goodrich David W

Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity

EZH2与DNA甲基化之间的相互作用介导神经内分泌前列腺癌谱系可塑性

Singh, Richa; Venkadakrishnan, Varadha Balaji; Imada, Eddie; Yamada, Yasutaka; Brady, Nicholas J; Dunmore, Kate E; Garner, Richard; Booker, Matthew A; Hanratty, Brian; Haffner, Michael C; Tolstorukov, Michael Y; Marchionni, Luigi; Robinson, Brian D; Rickman, David S; Beltran, Himisha

Morphine Tolerance Gated through EZH2-Mediated Suppression of Trpc5 in Spinal GABAergic Interneurons in Male Mice.

吗啡耐受性是通过 EZH2 介导的脊髓 GABA 能中间神经元中 Trpc5 的抑制而实现的。

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity

靶向Wnt/β-catenin和昼夜节律调节因子可恢复PRC2/EZH2控制的染色质二价性并抑制细胞状态多样性

Yang, Yatian; Zhang, Xiong; Venkadakrishnan, Varadha Balaji; Zou, Hongye; Zheng, Xingling; Guo, Shiyao; Chen, Christopher Z; Borowsky, Alexander D; Corey, Eva; Evans, Ronald M; Gao, Allen C; Dall'Era, Marc A; Zoubeidi, Amina; Lara, Primo N; Kung, Hsing-Jien; Chen, Xinbin; Beltran, Himisha; Chen, Hong-Wu

USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I

USP22 通过 EZH2 介导的 MHC-I 表观遗传沉默驱动肿瘤免疫逃逸和免疫检查点阻断耐药。

Liu, Kun; Iyer, Radhika; Li, Yi; Zhu, Jun; Cai, Zhaomeng; Wei, Juncheng; Cheng, Yang; Tang, Amy Y; Wang, Hai; Gao, Qiong; Mani, Nikita Lavanya; Marx, Noah; Gao, Beixue; Watterson, D Martin; Khan, Seema A; Gradishar, William J; Liu, Huiping; Fang, Deyu

EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway.

EZH2 与 RNA 甲基化的相互作用通过调节 m6A 自调节通路促进前列腺癌的进展。

Yi Yang, Fry Joshua, Yum Chaehyun, Wang Rui, Wu Siqi, Narayan Sharath, Liu Qi, Zhang Xingxing, Oo Htoo Zarni, Xie Ning, Li Yanqiang, Gao Xinlei, Yu Xufen, Hu Xiaoping, Li Qiaqia, Keseroglu Kemal, Özbudak Ertuğrul M, Abdulkadir Sarki A, Chen Kaifu, Jin Jian, Zhao Jonathan C, Dong Xuesen, Arango Daniel, Yang Rendong, Cao Qi

Phosphorylation-dependent modulation of the Lamin A/C-EZH2 complex regulates epithelial-mesenchymal plasticity.

Lamin A/C-EZH2 复合物的磷酸化依赖性调节调控上皮-间质可塑性。

Ak Balaji, Saha Santam, Sengupta Kundan